Press Releases
PreSens GmbH, in its eleventh year further on the pathway to success
PreSens Precision Sensing GmbH located in BioPark Regensburg is one of the few companies which without venture capital has succeeded in the development of products in the field of biosensory technology and since its foundation has been in the black financially. The innovative company has grown solely through its turnover in the last 11 years.
read on
Bavaria presents itself at Biolatina 2008 in Brazil
With an information stand, lectures and partnering with Brazilian and Argentinean biotechnology representatives, the State of Bavaria presented itself at the largest international conference in Latin America - Biolatina 2008, which took place from 29 September to 1 October in São Paulo, Brazil.
read on
AMAREG merges with Haupt Pharma and Wülfing Pharma
The Regensburg Pharmaceutical Company AMAREG GmbH has announced the merger with Haupt Pharma AG with headquarters in Berlin and Wülfing Pharma GmbH in Gronau/Leine, Germany. This has created the third largest company in the field of pharmaceutical manufacturers in Europe with 1,500 employees and a turnover of 180 Million €.
read on
BayernFIT invests further in BioRegio Regensburg
“Future through Innovation” - under this motto the State of Bavaria has started its new programme BayernFIT (Forschung/Research, Innovation, Technology). With the previously planned privatisation funds for the Transrapid to the sum of 490 million €, research and technology projects are being promoted throughout Bavaria. These include several projects for “Life Sciences” in BioRegio Regensburg. For the planned project BioPark III (3rd construction phase for BioPark Regensburg GmbH) 8 million € alone have been provided for.
read on
Bionorica AG successful in the market for plant-based medicines
The pharmaceutical company Bionorica AG located in BioRegio Regensburg from Neumarkt in Upper Palatinate, has doubled its revenue by almost double in the last three business years. Also in 2007 the German market leader for plant-based medicines significantly exceeded results of the 2006 business year, which until then had been by far the most successful. According to their figures for the 2007 business year, Bionorica produced an increased net turnover of 15.6% amounting to 114.9 million EUR. The company, distinguished abroad many times for its innovative power, has achieved a very good result.
read onARCHIVE
